AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred eHealth intervention
Number of subjects: 102
Study 37919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls with health care professionals
Number of subjects: 102
Study 37919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of participants' experiences
Number of subjects: 102
Study 37919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 102
Study 37919742 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive reduction of sodium intake (PR) in 24 facilities
Number of subjects: 1612
Study 37919742 — intervention group
Group type: COMPARATOR
Intervention: No reduction of sodium intake (NR) in 24 facilities
Number of subjects: 1612
Study 37919742 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive reduction of sodium intake (PR)
Number of subjects: 1612
Study 37919742 — intervention group
Group type: COMPARATOR
Intervention: No reduction of sodium intake (NR)
Number of subjects: 1612
Study 37919761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 163
Study 37919761 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 163
Study 37919761 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 163
Study 37919780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4932
Study 37919780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4932
Study 37919791 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP T3 level
Number of subjects: 5093
Study 37919791 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5093
Study 37919815 — intervention group
Group type: EXPERIMENTAL
Intervention: EaveTubes (ETs) + Long-Lasting Insecticidal Nets (LLINs)
Number of subjects: 1870
Study 37919815 — intervention group
Group type: COMPARATOR
Intervention: Long-Lasting Insecticidal Nets (LLINs) only
Number of subjects: 1870
Study 37919815 — intervention group
Group type: EXPERIMENTAL
Intervention: EaveTubes (ETs)
Number of subjects: 1870
Study 37919816 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/boosted lopinavir following 10 to 18 days of nutritional rehabilitation
Number of subjects: 52
Study 37919940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal therapy
Number of subjects: 46
Study 37920150 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma (4 units, 200-220 mL/unit, 2 units/day over two consecutive days)
Number of subjects: 120
Study 37920150 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 37920150 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma
Number of subjects: 120
Study 37920150 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid-19 convalescent plasma in immunocompromised patients
Number of subjects: 120
Study 37920192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (upload glucose data weekly for 4 months, receive support from diabetes care team)
Number of subjects: 120
Study 37920192 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diabetes support, same number of clinical visits as intensive group)
Number of subjects: 120
Study 37920410 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% Azelastine hydrochloride (AZE), two sprays per nostril twice daily for 4 weeks
Number of subjects: 581
Study 37920410 — intervention group
Group type: COMPARATOR
Intervention: 0.10% Azelastine hydrochloride (AZE), dosage not specified
Number of subjects: 581
Study 37920410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study 37920522 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm Guided Treatment (AGT)
Number of subjects: 581
Study 37920522 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 581
Study 37920607 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 340
Study 37920607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 37920733 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the transdiagnostic treatment of EDs
Number of subjects: 60
Study 37920779 — intervention group
Group type: EXPERIMENTAL
Intervention: MuST AKT intervention (standard care plus the MuST AKT intervention)
Number of subjects: 0
Study 37920779 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 37920793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet during pregnancy
Number of subjects: 0
Study 37920793 — intervention group
Group type: COMPARATOR
Intervention: Regular diet during pregnancy
Number of subjects: 0
Study 37920802 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair propulsion fatigue protocol (15-min duration, three 4-min rounds with 90 s rest)
Number of subjects: 50
Study 37920833 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine 48 mg with selegiline (5 mg/d for 7 days)
Number of subjects: 15
Study 37920833 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 48 mg alone
Number of subjects: 15
Study 37920858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment on days 1 and 2 in addition to standard postoperative pain management
Number of subjects: 80
Study 37920858 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative pain management
Number of subjects: 80
Study 37920859 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-tack needle acupuncture
Number of subjects: 24
Study 37920859 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 37920915 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat + gemcitabine + nab-paclitaxel
Number of subjects: 0
Study 37920921 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + nab-paclitaxel
Number of subjects: 0
Study 37920963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 150-300 mg/day
Number of subjects: 35
Study 37920963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 300 mg/day
Number of subjects: 35
Study 37920963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 37920963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 35
Study 37921006 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT ON (continuation of antiarrhythmic drug therapy)
Number of subjects: 200
Study 37921006 — intervention group
Group type: COMPARATOR
Intervention: ADT OFF (discontinuation of antiarrhythmic drug therapy)
Number of subjects: 200
Study 37921006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ADT ON and ADT OFF)
Number of subjects: 200
Study 37921006 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT ON and ADT OFF
Number of subjects: 200
Study 37921353 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated continuous theta burst stimulation (cTBS)
Number of subjects: 40
Study 37921353 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 37921410 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (three different doses)
Number of subjects: 0
Study 37921410 — intervention group
Group type: COMPARATOR
Intervention: HDCV (Imovax rabies®)
Number of subjects: 0
Study 37921461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 371
Study 37921461 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (active control)
Number of subjects: 371
Study 37921522 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic drop, 1 drop 4 times daily for 52 weeks
Number of subjects: 208
Study 37921522 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group in GOBI study)
Number of subjects: 208
Study 37921599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Visceral-Peritoneal Debulking (L-VPD)
Number of subjects: 208
Study 37921599 — intervention group
Group type: COMPARATOR
Intervention: Visceral-Peritoneal Debulking (VPD)
Number of subjects: 208
Study 37921644 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by GNRI (Geriatric Nutritional Risk Index)
Number of subjects: 2775
Study 37921644 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by PNI (Prognostic Nutritional Index)
Number of subjects: 2775
Study 37921644 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional status assessed by CONUT (Controlling Nutritional Status)
Number of subjects: 2775
Study 37921644 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative AKI incidence
Number of subjects: 2775
Study 37921644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional indices in AKI prediction models
Number of subjects: 2775
Study 37921755 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant (10, 30, 90, or 250 mg)
Number of subjects: 175
Study 37921755 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant (100 mg) + Palbociclib (125 mg) ± LHRH agonist
Number of subjects: 175
Study 37921755 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant (single-agent) ± LHRH agonist
Number of subjects: 175
Study 37921755 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant (100 mg)
Number of subjects: 175
Study 37921769 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrauterine placental perfusion (EPP)
Number of subjects: 60
Study 37921769 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 60
Study 37921846 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Skills Training (REST)
Number of subjects: 166
Study 37921846 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (VCT-based problem-solving individual therapy)
Number of subjects: 166
Study 37922035 — intervention group
Group type: EXPERIMENTAL
Intervention: P140 peptides
Number of subjects: 0
Study 37922035 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant drug apocynin
Number of subjects: 0
Study 37922055 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) with ethylene vinyl alcohol copolymer (EVOH)
Number of subjects: 10
Study 37922156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (administrative support, educational resources, storytelling initiative, performance reports)
Number of subjects: 20375
Study 37922156 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20375
Study 37922279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention combined with progressive muscle relaxation (self-practice daily for three weeks)
Number of subjects: 24
Study 37922279 — intervention group
Group type: COMPARATOR
Intervention: Standard care (health assessment, regular health advice, and nutrition consultation)
Number of subjects: 24
Study 37922279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention combined with progressive muscle relaxation
Number of subjects: 24
Study 37922279 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 37922432 — intervention group
Group type: EXPERIMENTAL
Intervention: Early trends of OS prognostic biomarkers (ROPRO and DeepROPRO)
Number of subjects: 19920
Study 37922432 — intervention group
Group type: EXPERIMENTAL
Intervention: Early OS within the joint model (JM) framework
Number of subjects: 19920
Study 37922438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of PSMA-targeting alpha emitter via antibody delivery
Number of subjects: 32
Study 37922442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Hyperthermic Intraperitoneal Chemotherapy
Number of subjects: 0
Study 37922442 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37922692 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy/cancer immunotherapy
Number of subjects: 464
Study 37922692 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 464
Study 37922694 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary protein intake (total, animal, plant)
Number of subjects: 2709
Study 37922883 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRSs) implementation in primary care
Number of subjects: 0
Study 37922883 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recruitment strategies for underrepresented race and ethnicity groups
Number of subjects: 0
Study 37922910 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 immunotherapy combined with standard-of-care chemo-hormonal therapy
Number of subjects: 0
Study 37922910 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemo-hormonal therapy
Number of subjects: 0
Study 37922930 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of lutetium-177
Number of subjects: 43
Study 37922989 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 159
Study 37922989 — intervention group
Group type: COMPARATOR
Intervention: Anti-CD20 radioimmunotherapy (RIT)
Number of subjects: 159
Study 37923161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day, N = 45)
Number of subjects: 87
Study 37923161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 42)
Number of subjects: 87
Study 37923301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 40
Study 37923301 — intervention group
Group type: COMPARATOR
Intervention: Continuous Spontaneous Breathing (CSB)
Number of subjects: 40
Study 37923345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified balanced energy-protein (BEP) supplement during pregnancy and lactation
Number of subjects: 100000
Study 37923345 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 100000
Study 37923529 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37923615 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-targeted training on nonpharmacological pain management
Number of subjects: 64
Study 37923615 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological methods (control group)
Number of subjects: 64
Study 37923987 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) followed by four cycles of FOLFOX (oxaliplatin, 5-fluorouracil, and folinic acid) as a neoadjuvant treatment.
Number of subjects: 364
Study 37923987 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) (45-50.4 Gy in 25-28 fractions, 5 times a week) concurrently with capecitabine or 5-fluorouracil.
Number of subjects: 364
Study 37923987 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT followed by FOLFOX chemotherapy.
Number of subjects: 364
Study 37923987 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT).
Number of subjects: 364
Study 37924021 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed zirconia crowns (ZCs)
Number of subjects: 20
Study 37924021 — intervention group
Group type: COMPARATOR
Intervention: Stainless-steel crowns (SSCs)
Number of subjects: 20
Study 37924063 — intervention group
Group type: EXPERIMENTAL
Intervention: Introvision training (experimental group)
Number of subjects: 51
Study 37924063 — intervention group
Group type: COMPARATOR
Intervention: Introvision training (experimental group) and waiting list group (pooled data)
Number of subjects: 51
Study 37924084 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental LPS challenge
Number of subjects: 10
Study 37924084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation LPS challenge
Number of subjects: 10
Study 37924083 — intervention group
Group type: COMPARATOR
Intervention: TECH (Fitbit, step goals, app, feedback)
Number of subjects: 116
Study 37924083 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH + Gamification
Number of subjects: 116
Study 37924083 — intervention group
Group type: COMPARATOR
Intervention: TECH (Fitbit)
Number of subjects: 116
Study 37924101 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 teleconsultations of 45 min with a psychologist
Number of subjects: 932
Study 37924154 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT imaging
Number of subjects: 117
Study 37924247 — intervention group
Group type: EXPERIMENTAL
Intervention: Online exposure and response prevention therapy for 10 weeks
Number of subjects: 224
Study 37924247 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducation for 10 weeks
Number of subjects: 224
Study 37924356 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training with Rocabado exercises
Number of subjects: 0
Study 37924356 — intervention group
Group type: COMPARATOR
Intervention: Rocabado exercises (Control)
Number of subjects: 0
Study 37924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 619
Study 37924483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 1862
Study 37924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithms for dysphagia management
Number of subjects: 0
Study 37924574 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapeutic options such as neurostimulation
Number of subjects: 0
Study 37924624 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch- and sucrose-reduced diet for 4 weeks
Number of subjects: 2
Study 37924716 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary auricular reconstructions based on the Nagata method
Number of subjects: 7
Study 37924716 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection surgeries only (Cases 5 and 6)
Number of subjects: 7
Study 37924833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 once monthly
Number of subjects: 544
Study 37924833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 once every 2 months
Number of subjects: 544
Study 37924833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 37924833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous TV-46000 (both groups)
Number of subjects: 544
Study 37924841 — intervention group
Group type: EXPERIMENTAL
Intervention: VRE colonisation present in 49 (20%) participants; environmental surfaces contaminated in 36 (73%) of these patients.
Number of subjects: 245
Study 37924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure within the past 30 days (high-risk antibiotics p=0.011 and low-risk antibiotics p=0.0004)
Number of subjects: 245
Study 37924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure (adjusted odds ratio 2.75 [95% CI 1.22-6.16]) and male sex (2.75 [1.24-6.08])
Number of subjects: 245
Study 37924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical dependence (0.91 [0.83-0.99])
Number of subjects: 245
Study 37924856 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS 10 mg
Number of subjects: 205
Study 37924856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 37924939 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold Glider (WOGG)
Number of subjects: 78
Study 37924939 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlider (PG)
Number of subjects: 78
Study 37924939 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 37925053 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string double-layer closure (Turan technique) for uterine incision repair
Number of subjects: 0
Study 37925316 — intervention group
Group type: EXPERIMENTAL
Intervention: LVRNA009 (25, 50, and 100 μg)
Number of subjects: 72
Study 37925363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) 45/200 mg once-daily orally for 12 weeks (chemotherapy treatment group)
Number of subjects: 22
Study 37925363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no malignancy)
Number of subjects: 22
Study 37925394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducational program
Number of subjects: 332
Study 37925402 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of London's Ultra Low Emission Zone (ULEZ)
Number of subjects: 0
Study 37925402 — intervention group
Group type: COMPARATOR
Intervention: Luton (comparator site)
Number of subjects: 0
Study 37925450 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal peer PrEP referral + HIVST delivery
Number of subjects: 80
Study 37925450 — intervention group
Group type: COMPARATOR
Intervention: Informal peer PrEP referral
Number of subjects: 80
Study 37925471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg twice daily (up to 30 mg twice daily)
Number of subjects: 212
Study 37925471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 5 mg twice daily
Number of subjects: 212
Study 37925512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) guided surfactant therapy
Number of subjects: 668
Study 37925512 — intervention group
Group type: COMPARATOR
Intervention: Standard surfactant therapy
Number of subjects: 668
Study 37925557 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS) treatment, 10 daily sessions in clinical trial one
Number of subjects: 30
Study 37925557 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS) treatment, 20 daily sessions in clinical trial two
Number of subjects: 30
Study 37925660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4404
Study 37925660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4404
Study 37925660 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 4404
Study 37925660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4404
Study 37925660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both dosages)
Number of subjects: 4404
Study 37925660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 4404
Study 37925960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA tACS
Number of subjects: 60